Why Migraine and Other Headache Disorders Are a Good Fit for Decentralized Clinical Trials

Characterized by recurring episodes of moderate to severe headache, elevated sensitivity to sound and/or light and other unpleasant symptoms, migraines can often be debilitating for the roughly 35 million people in the U.S. who suffer from this condition.

The current model for clinical research in migraine may fail to accurately capture the whole effect this disorder has on persons with migraine. In his latest insight brief, Dr. David Kudrow, M.D. explains how decentralized clinical trial (DCT) technologies can help to improve the patient experience from enrollment through trial completion — with numerous benefits to sponsors and research organizations as well.

Fill in the form and get access to these insights today.